Structured Linezolid Dose Reduction Shows Promise in Drug-Resistant TB Treatment
Key Insights
A multicentric randomized trial of 378 patients with pre-extensively drug-resistant tuberculosis (search) found that structured linezolid dose reduction regimens achieved comparable 88% recurrence-free cure rates to standard 600mg dosing when combined with bedaquiline and pretomanid.
Most tuberculosis recurrences occurred within the first 24 weeks after treatment completion, with 11 of 14 cases happening within six months, emphasizing the need for intensive early post-treatment monitoring.
No patients developed acquired resistance to bedaquiline, pretomanid, or linezolid at recurrence, suggesting these drugs could potentially be reused in subsequent treatment regimens.
A large multicentric randomized clinical trial in India has demonstrated that structured dose reduction of linezolid in combination with bedaquiline and pretomanid (BPaL) achieves comparable long-term effectiveness to standard dosing in treating pre-extensively drug-resistant tuberculosis (search), while potentially reducing treatment-limiting toxicities.
The pragmatic trial enrolled 403 patients with pre-extensively drug-resistant (PreXDR) pulmonary tuberculosis across multiple centers in India. Of these, 378 patients were included in the modified intent-to-treat analysis based on baseline sputum culture positivity and drug sensitivity. Participants were randomized to three treatment arms: standard linezolid 600mg for 26 weeks (arm 1), structured dose reduction from 600mg to 300mg after nine weeks (arm 2), or dose reduction after 13 weeks (arm 3).
Comparable Long-Term Outcomes Across Treatment Arms
At 48 weeks post-treatment follow-up, recurrence-free cure rates were remarkably similar across all three arms: 87% in the standard dose group, 88% in the nine-week reduction group, and 88% in the 13-week reduction group. Overall, 331 of 378 patients (88%) achieved recurrence-free cure, with the structured dose reduction arms demonstrating non-inferiority to the standard regimen.
"The structured dose reduction arms had comparable recurrence free cure rates as linezolid 600 mg arm when given along with bedaquiline and pretomanid for 26 weeks in PreXDR TB," the researchers concluded.
Early Recurrence Pattern Identified
Among the 14 patients who experienced recurrence during follow-up, a clear temporal pattern emerged. Eleven recurrences (79%) occurred within the first 24 weeks after treatment completion, with four cases appearing within the first 12 weeks. This finding has important implications for post-treatment monitoring strategies.
Whole genome sequencing analysis of paired samples from baseline and recurrence revealed that eight of ten analyzed cases represented endogenous reactivation (relapse) with the same mycobacterial strain, while only two cases were exogenous reinfections with different strains. The predominant lineage at recurrence was lineage 2, observed in nine patients, followed by lineage 3 in three patients and lineage 4 in two patients.
Absence of Acquired Drug Resistance
A particularly encouraging finding was the complete absence of acquired resistance to the three study drugs. All 11 culture-positive isolates at recurrence remained sensitive to bedaquiline, pretomanid, and linezolid, as well as to clofazimine and delamanid. This observation suggests these medications could potentially be considered for retreatment regimens, though the researchers noted this would require further study.
"None of the patients in our cohort had acquired resistance to bedaquiline, pretomanid and linezolid at the time of recurrence," the study authors reported. "These evidences strengthen the implementation plan of BPaL-based regimens in the National Programmes for the management of highly drug-resistant forms of TB."
Treatment Response Predictors
The analysis identified two key indicators of favorable treatment outcomes through multivariable analysis. Sputum culture conversion within nine weeks of treatment initiation was associated with significantly better outcomes (hazard ratio 0.42, 95% CI 0.2-0.87, p=0.02). Similarly, weight gain exceeding five kilograms during treatment predicted favorable responses (hazard ratio 0.31, 95% CI 0.13-0.74, p=0.01).
Notably, baseline characteristics including age, nutritional status, and extent of lung lesions were not predictive of treatment outcomes, suggesting that treatment response indicators may be more valuable than initial patient characteristics for prognostic assessment.
Toxicity Management Benefits
The structured dose reduction approach showed promise for managing linezolid-associated toxicities. Most treatment-related adverse events, including anemia, thrombocytopenia, and peripheral neuropathy, resolved during or shortly after treatment completion. At 48 weeks post-treatment, only six patients across all arms had persistent linezolid-related adverse events.
The researchers noted that "switching to lower doses of linezolid might result in better tolerance and fewer recurrent adverse events," supporting the rationale for the dose reduction strategy.
Global Context and Implications
The study's findings align with other recent BPaL trials. The ZeNiX trial showed 89% favorable outcomes at 78 weeks post-treatment follow-up, while the TB PRACTECAL trial reported 23% unfavorable composite outcomes at 72 weeks post-randomization. The current study's 88% recurrence-free cure rate at 48 weeks post-treatment demonstrates consistency with these international results.
Globally, an estimated 400,000 people developed multidrug-resistant or rifampicin-resistant tuberculosis (search) in 2023, with India accounting for 27% of cases. The successful implementation of bedaquiline-based regimens has increased global treatment success rates to 68%, making these findings particularly relevant for high-burden countries.
Clinical Practice Implications
The World Health Organization currently recommends two-year follow-up for drug-resistant tuberculosis (search) patients after treatment completion. This study's findings support intensive monitoring during the first year, particularly the initial six months, when most recurrences occur.
The comparable effectiveness of structured dose reduction regimens offers clinicians flexibility in managing linezolid toxicities while maintaining treatment efficacy. This approach could be particularly valuable in resource-limited settings where treatment interruptions due to adverse events can compromise outcomes.
The research team emphasized that "post-treatment follow-up of patients on BPaL-based regimen during the first one year is vital, as most of the recurrences occurred within the first six months."